Alkylating agents: all 3,295 studies that test it

Page 18 of 33. Open to participants first (456), then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety of UGN-101 in Recurrent PatientsWithdrawnNCT04006691Phase 3
• Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid TumorsTerminatedNCT03992326Phase 1
• Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic LeukemiaCompletedNCT03991884Phase 1
• Optimizing PTCy Dose and TimingActive, not recruitingNCT03983850Phase 1/2
• BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD)Status unknownNCT03982771Phase 2
• Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic TransplantCompletedNCT03961919Phase 2
• Exploring Durable Remission With Rituximab in Antineutrophil Cytoplasmic Antibody(ANCA)-Associated VasculitisStatus unknownNCT03942887Phase 3
• Cyclophosphamide in the Treatment of Associated Acquired Lipodystrophy Syndrome With Type 1 DiabetesActive, not recruitingNCT03936829Not applicable
• First-line Chemotherapy With Temozolomide Alone for Non-enhancing Adult Brainstem Gliomas, With a Diffuse Subtype and Showing Clinical and/or Radiological Infiltrative Pattern of ProgressionStatus unknownNCT03932981Phase 2
• A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic LeukemiaActive, not recruitingNCT03914625Phase 3
• Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant CyclophosphamideActive, not recruitingNCT03910452Early Phase 1
• A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's SyndromeActive, not recruitingNCT03899337Phase 2
• Dose-adjusted Adjuvant FEC Compared to Standard FEC for Breast CancerCompletedNCT03888677Phase 3
• A Study to Evaluate the Safety of LAM561 Added to Standard of Care in Newly-diagnosed Glioblastoma PatientsCompletedNCT03867123Phase 1
• 'ADVANCE' (A Pilot Trial)Active, not recruitingNCT03858322Phase 1
• Targeting the Tumor Microenvironment in R/M SCCHNStatus unknownNCT03844763Phase 1/2
• DLCL002 Protocol for Patients With High Risk Aggressive B-cell LymphomaStatus unknownNCT03837873Phase 2
• Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid TumorsActive, not recruitingNCT03836352Phase 2
• NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal CancerCompletedNCT03832621Phase 2
• Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line ChemotherapyActive, not recruitingNCT03830918Phase 1/2
• Autologous Transplant To End NMO Spectrum DisorderWithdrawnNCT03829566Phase 2/3
• STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMAActive, not recruitingNCT03829371Phase 4
• A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)Active, not recruitingNCT03821610Phase 2
• The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian CancerStatus unknownNCT03814447Early Phase 1
• MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian CancerStatus unknownNCT03799913Early Phase 1
• Early Temozolomide in Patients With High-Grade Gliomas in RehabilitationWithdrawnNCT03796507Early Phase 1
• Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM)Status unknownNCT03795597Phase 1/2
• BuCE Versus BuME as Conditioning Therapy in Non-Hodgkin's LymphomaCompletedNCT03794167Phase 2
• Busulfan, Melphalan and Etoposide as Conditioning for Autologous Transplantation for Non-Hodgkin's Lymphoma (NHL)CompletedNCT03792815Phase 2
• Sequential Combination Therapy in Bladder CancerStatus unknownNCT03790384Phase 4
• Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients with Relapsed/refractory CLLCompletedNCT03787264Phase 2
• TTFields Together With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GBMStatus unknownNCT03780569Not applicable
• HFSRT With Concurrent TMZ for Large BMsStatus unknownNCT03778541Phase 3
• Cyclophosphamide and Azathioprine vs Tacrolimus in Antisynthetase Syndrome-related Interstitial Lung DiseaseStatus unknownNCT03770663Phase 3
• Lentivirally Redirected CD123 Autologous T Cells in AMLTerminatedNCT03766126Phase 1
• Efficacy and Safety of the Cryopreserved Formulation of OTL-101 in Subjects With ADA-SCIDCompletedNCT03765632Phase 1/2
• Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17Active, not recruitingNCT03755804Phase 2
• Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast CancerStatus unknownNCT03749850Phase 1
• BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCTStatus unknownNCT03733327Phase 2/3
• Temozolomide Combine With Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost for Non Small Cell Lung Cancer Brain MetastasesStatus unknownNCT03732482Phase 2/3
• Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine CancerCompletedNCT03728361Phase 2
• Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple MyelomaStatus unknownNCT03716856Phase 1
• CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple MyelomaActive, not recruitingNCT03710421Phase 1
• Cyclophosphamide as Graft-versus-host Prophylaxis After Allogeneic Stem Cell Transplantation for Multiple MyelomaCompletedNCT03700450Phase 2
• Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedNCT03691376Phase 1
• A Study of the Safety and Pharmacokinetics of BRCX014 in Patients With GlioblastomaStatus unknownNCT03687034Phase 1
• Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung CancerActive, not recruitingNCT03672773Phase 2
• IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver CancerActive, not recruitingNCT03655002Phase 1
• Improved Post-Transplant Cyclophosphamide Regimens for Pediatric Patients With Refractory AMLStatus unknownNCT03654703Phase 2
• A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell DiseaseCompletedNCT03653247Phase 1/2
• Efficacy of Two Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade GliomaStatus unknownNCT03633552Phase 3
• Conditioning SCID Infants Diagnosed EarlyActive, not recruitingNCT03619551Phase 2
• Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma PatientsStatus unknownNCT03617432Phase 2
• The Efficacy of Salvage BGD With autoSCT Consolidation in Advanced Classical HL Patients Not Responding to ABVDCompletedNCT03615664Phase 2
• Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPNActive, not recruitingNCT03613532Phase 1
• A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI MalignanciesStatus unknownNCT03607643Phase 1/2
• SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid TumorsCompletedNCT03604679Phase 1
• Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell TransplantationWithdrawnNCT03602898Phase 2
• High Dose Ascorbic Acid for Plasma Cell DisordersCompletedNCT03602235Phase 1
• Therapeutic Targeting of Sex Differences in Pediatric Brain Tumor GlycolysisTerminatedNCT03591861Not applicable
• Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid TumorsTerminatedNCT03585465Phase 1/2
• Liver Transplantation With Tregs at MGHCompletedNCT03577431Phase 1/2
• BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)Active, not recruitingNCT03576378Phase 1/2
• A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell ReinfusionStatus unknownNCT03570983Phase 2
• SGT-53 in Children With Recurrent or Progressive CNS MalignanciesWithdrawnNCT03554707Early Phase 1
• Anti-inflammatory Treatment for Inactive Takayasu ArteritisStatus unknownNCT03550781Phase 2/3
• RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis FactorCompletedNCT03536039Phase 2
• T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic AnemiaActive, not recruitingNCT03531736Phase 1
• Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCTStatus unknownNCT03530085Phase 2/3
• TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed GlioblastomaCompletedNCT03529448Phase 1/2
• Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLLCompletedNCT03524235Phase 1
• Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast CancerCompletedNCT03518242Phase 1
• Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid LeukemiaWithdrawnNCT03515707Phase 2
• TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple MyelomaWithdrawnNCT03506802Phase 1
• Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic SyndromeSuspendedNCT03494569Phase 1
• First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 YearsCompletedNCT03492775Phase 2
• CYCLONES - CYClophosphamide LOw Dose and No Extra SteroidTerminatedNCT03492255Not applicable
• Pre-operative RT and TMZ in Patients With Newly Diagnosed GBM Diagnosed Glioblastoma. A Phase I Study. (PARADIGMA)WithdrawnNCT03480867Phase 1
• Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)Active, not recruitingNCT03477500Phase 3
• Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With GlioblastomaCompletedNCT03477110Early Phase 1
• Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid LeukemiaActive, not recruitingNCT03467386Phase 1
• CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALLActive, not recruitingNCT03467256Phase 1/2
• Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma)Status unknownNCT03463733Phase 1
• Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With MyelomaTerminatedNCT03448978Phase 1
• HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal MelanomaStatus unknownNCT03435302Phase 3
• AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin LymphomaActive, not recruitingNCT03434769Phase 1
• Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary MyelofibrosisCompletedNCT03426969Early Phase 1
• A Longitudinal Assessment of Tumor Evolution in Patients With Brain CancerCompletedNCT03425292Phase 1
• A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced MelanomaStatus unknownNCT03422445Phase 2
• Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid TumorsTerminatedNCT03420963Phase 1
• Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 SignalingStatus unknownNCT03412643Phase 2
• Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for TransplantationCompletedNCT03402295Phase 3
• CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomasTerminatedNCT03387592Phase 2
• Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCTStatus unknownNCT03385096Phase 2/3
• Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal CancerStatus unknownNCT03381352Phase 2
• Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple MyelomaStatus unknownNCT03380039Not applicable
• Irinotecan and Temozolomide for Ewing SarcomaStatus unknownNCT03359005Phase 2
• A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly PatientsActive, not recruitingNCT03352765Phase 1
• Two Chemotherapy Regimens Plus or Minus BevacizumabActive, not recruitingNCT03351296Phase 2
• Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and AdolescentsWithdrawnNCT03349346Phase 1

← Alkylating agents overview